Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 10NIH 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

CNS 14Sarcoma 12Thoracic 5Gastrointestinal 5Gynecologic 3Dermatologic 3Breast 3Head & Neck 2Other solid neoplasm 1Genitourinary 1Endocrine 1

Conditions

Pheochromocytoma 1Adrenal Gland Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 17Specimen Handling 13lutetium Lu 177 dotatate 7gallium Ga 68 dotatate 7Cisplatin 7cabozantinib 6pazopanib 5Sorafenib 5Fluorodeoxyglucose F18 5Everolimus 5Etoposide 4romidepsin 3olaparib 3fluorodopa F 18 3cixutumumab 3X-Rays 3Temozolomide 3Sunitinib 3Radiotherapy 3Nivolumab 3Ipilimumab 3Iodine-131 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2belinostat 2aldesleukin 2aflibercept 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Surgical Procedures, Operative × Endocrine × Clear all
NCT01348698 2018-11-26

Evaluation of Molecular Markers in Adrenal Tumors

National Institutes of Health Clinical Center (CC)

Terminated
74 enrolled 10 charts
Endocrine

Adrenal Gland Neoplasms, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡